We provide evidence that the IFN-regulated member of the Schlafen (SLFN) family of proteins, SLFN5, promotes the malignant phenotype in glioblastoma multiforme (GBM). Our studies indicate that SLFN5 expression promotes motility and invasiveness of GBM cells, and that high levels of SLFN5 expression correlate with high-grade gliomas and shorter overall survival in patients suffering from GBM. In efforts to uncover the mechanism by which SLFN5 promotes GBM tumorigenesis, we found that this protein is a transcriptional co-repressor of STAT1. Type-I IFN treatment triggers the interaction of STAT1 with SLFN5, and the resulting complex negatively controls STAT1-mediated gene transcription via interferon stimulated response elements. Thus, SLFN5 is both an IFN-stimulated response gene and a repressor of IFN-gene transcription, suggesting the existence of a negative-feedback regulatory loop that may account for suppression of antitumor immune responses in glioblastoma.
INTRODUCTION
Glioblastoma multiforme (GBM), an aggressive tumor with a highly heterogeneous genetic background, is the most common central nervous system neoplasm in adults. 1 Currently available therapies for GBM frequently fail due to the highly infiltrative GBM growth patterns and the presence of chemotherapy-resistant tumor initiating cancer stem cells. 2, 3 Because of the high mortality and morbidity of these tumors and the limited treatment options, there is an urgent need for the development of novel therapeutic strategies to target and eliminate resistant cancer stem cells.
Type-I interferons (IFNs), specifically IFN-α and IFN-ß, exhibit important antineoplastic properties in vitro and in vivo against a wide variety of malignancies. 4, 5 There has been some evidence for type-I IFN antitumor activity in GBM in vitro and in vivo, but this primarily involves studies of IFN combinations with chemotherapeutic agents. 6 IFNβ treatment has been shown to sensitize human glioma cells to temozolomide treatment in vitro, 7 and in some cases may have a beneficial therapeutic effect when incorporated in the therapeutic regimen of GBM patients. 8 The efficacy of stand-alone IFN treatment is generally low, suggesting that some GBM cells may develop resistance to IFN-treatment in vivo. 9 The mechanisms of IFN-α/β signaling have been extensively defined. It is now well established that engagement of the type-I IFN receptor, IFNAR, leads to STAT-dependent transcriptional activation of several IFN-stimulated genes (ISGs) that mediate the biological responses of Type-I IFNs. 10, 11 Several mouse and human members of the Schlafen family of proteins are IFN inducible (reviewed in Mavrommatis et al. 12 ). In previous studies we demonstrated that human Schlafen 5 (SLFN5) is a type-I IFNregulated ISG in different cell types. 13, 14 The protein is composed of an AAA domain, a unique SLFN box and a predicted transcriptional regulatory area with a helix-turn-helix domain (COG2865). 12, 15 Other studies established that several SLFN genes are upregulated in melanoma and renal cell carcinoma cell lines following IFN treatment. 13, 14 In the present study, we investigated the patterns of expression of different human SLFNs in GBM and examined the role of SLFN5 in GBM progression and the induction of IFN-induced biological responses. Our data establish that SLFN5 expression positively correlates with the GBM malignant phenotype and provide evidence for a novel mechanism by which this may occur, involving SLFN5-mediated repression of IFN-induced STAT1 transcriptional activity.
RESULTS

SLFN5 expression is associated with poor survival in GBM patients
In initial studies we sought to define the patterns of expression of human SLFN genes in primary malignant cells from GBM patients, using publicly available microarray databases. We first assessed the relative expression levels of SLFN5, SLFN11, SLFN12 and SLFN13 genes in the Oncomine database, 16 using data from the SUN 17 data set. Differential expression analysis revealed a statistically significant increase in SLFN5 (5.6-fold difference, P = 1.78e-10), and to a lesser extent SLFN11 (1.47-fold difference, P = 0.004), SLFN12 (1.9-fold difference, P = 1.19e-4) and SLFN13 (3.13-fold difference, P = 4.81e-5) transcripts ( Figure 1a ). Next, we enquired whether high expression levels of SLFN genes correlate with poor survival in GBM patients using the REMBRANDT (repository for molecular brain neoplasia data) database. 18 GBM patients expressing high levels of SLFN5 (P = 0.00528), SLFN11 (P = 0.0421), SLFN12 (P = 1.04e-5) and SLFN13 (P = 0.00249) had shorter overall survival compared with patients expressing low levels for the respective SLFN genes (Figure 1b ). We further explored the relationship between SLFN5, SLFN11, SLFN12 and SLFN13 and glioma grade. We found that SLFN5, SLFN11 and SLFN12 expression levels increase with glioma grade and are highest in grade IV (that is, GBM), when compared to grade I, grade II or grade III gliomas ( Figure 1c ). Human SLFNs are over-expressed in primary cells from GBM patients and correlate with poor overall survival. (a) SLFN5, SLFN11, SLFN12 and SLFN13 relative gene expression levels are shown in normal brain tissue (light blue, n = 23) versus GBM patient samples (dark blue, n = 81) using Sun et al. 17 data set available through Oncomine database. 16 (b) Kaplan-Meier survival plots showing percent of survival between GBM patients with high (n = 329) versus low (n = 523) expression levels of SLFN5, SLFN11, SLFN12 and SLFN13. Data were extracted from REMBRANDT database. 18 (c) SLFN5, SLFN11, SLFN12 and SLFN13 expression data were analyzed using REMBRANDT-cohort of patients with grade I, grade II, grade III, and grade IV gliomas (GBM). Plots were generated using the GlioVis online tool (http://gliovis.bioinfo.cnio.es). , medulloblastoma cell lines (c) and human normal astrocytes SVGp12 (d). Indicated cells were left untreated (UT) or were treated with human IFNα or IFNβ for 6 h. Quantitative reverse transcription PCR (qRT-PCR) analyses of the relative messenger RNA (mRNA) expression of SLFN5, SLFN11, SLFN12, SLFN13 and SLFN14 genes are shown. Data are expressed as fold change over untreated controls, and bar graphs represent means ± s.e.m. of three independent experiments for LN18, LN443, SVGp12 and four independent experiments for JK18, JK46, DAOY, D556, LN229 and U87MG. (Und: undetected). (e) Left panel, expression of human SLFN proteins in GBM, medulloblastoma cell lines and normal brain tissue lysates. The cells were lysed and equal amounts of whole-cell lysates were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Immunoblots were probed with antibodies against SLFN5, SLFN11, SLFN12L and GAPDH, as indicated. Immunoblot images are representative of five independent experiments for SLFN5, SLFN11 and two independent experiments for SLFN12L. Right panels, bands from five SLFN5, SLFN11 or two SLFN12L independent experiments (including the blots shown) were quantified by densitometry using Image J software and normalized and reported relative to GAPDH.
Type-I IFN-dependent human SLFN expression in established and patient-derived cell lines As previous studies from our group had demonstrated that SLFNs are ISGs in other tissues, we next evaluated the effects of type-I IFN treatment on the expression of different SLFN genes in several malignant brain tumor cell lines. SLFN5 was the most prominent inducible gene in response to IFNα-treatment in most cases, while the inducible expression of SLFN11, SLFN12 and SLFN13 was more variable (Figures 2a-d) . In patient-derived glioma stem cell (GSC) lines, 19, 20 we found that SLFN5 was highly expressed (data not shown), whereas SLFN11, SLFN12, SLFN13 and SLFN14 appeared to be expressed to a lesser extent ( Figure 2b ). Treatment with IFNα or IFNβ of GSCs markedly induced SLFN5 expression, confirming our observation in established GBM cell lines ( Figure 2b ). Interestingly, there was minimal induction of SLFN genes in normal astroglial cells (Figure 2d ), consistent with selective IFN-dependent induction of SLFN5 expression in malignant brain tumor cells. Next, we analyzed the expression of different human SLFN proteins in different glioblastoma (LN18, LN229, LN443 and U87MG) and medulloblastoma (DAOY and D556) cell lines. SLFN5 expression was higher in all brain tumor cell lines compared to normal brain tissue (Figure 2e ). Similarly, SLFN12L protein was expressed at higher levels in malignant cells compared to normal brain cells (Figure 2e ), while there was less consistency for the levels of expression of SLFN11. Together, these results indicate that SLFN proteins, in particular SLFN5, are over-expressed in malignant brain tumor cells.
Effects of SLFN5 on glioblastoma tumor formation, growth and invasion
To define the effects of SLFN5 expression on GBM cellular proliferation, invasion and in vivo growth, we generated U87MG SLFN5 knockout (KO) cells. Plasmids encoding Cas9 and singleguide RNAs targeting the SLFN5 gene (Supplementary Figure S1A ) were transfected into U87MG cells and clones were selected in puromycin. Western immunoblot analysis confirmed the lack of endogenous SLFN5 expression compared to U87MG SLFN5 wild type (WT) cells transfected with non-targeting single-guide RNA/ Cas9-expressing plasmid (Figure 3a ). To investigate the effects of targeted gene disruption of SLFN5 on cell proliferation and viability, we used an Alamar Blue-based cell viability assay. Decreased proliferation of SLFN5 KO cells compared to SLFN5 WT cells was observed in time course studies ( Figure 3b ). In addition, shRNA mediated SLFN5 knockdown in LN18 and U87MG cells reduced anchorage-independent growth in soft agar (Supplementary Figure S1B ). Next, we tested the invasive properties of SLFN5 WT and SLFN5 KO U87MG cells using matrigel-based (Figures 3c and d ) and three-dimensional tumor spheroid invasion assays 21 (Figures 3e and f ). Depletion of SLFN5 expression reduced the invasive properties of U87MG cells in both assays (Figures 3cf), suggesting that SLFN5 plays an important role in GBM invasion. When U87MG SLFN5 WT and KO cells were injected subcutaneously into athymic nu/nu mice, we found that targeted disruption of SLFN5 gene expression delayed tumor formation and decreased tumor growth in vivo (Figures 3g and h).
Effects of SLFN5 depletion on the glioblastoma transcriptome
To gain further insight into the possible mechanism by which SLFN5 depletion mediates these observed biological changes, we performed a high-throughput paired-end RNA-sequencing on total RNA from SLFN5 depleted cells. To identify differentially regulated genes, we applied Cuffdiff analysis (Supplementary Materials and Methods) to the entire data set. We identified 238 genes ( Supplementary Table S1 ) in total, 124 differentially expressed isoforms ( Supplementary Table S2 ) and 146 differentially expressed primary transcripts ( Supplementary Table S3 ) that met FDR criteria q value o10% of differential expression in KO cells compared to parental U87MG. To identify globally affected cellular processes and functions, we performed gene set enrichment analyses, using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 approach. Gene set enrichment analysis demonstrated over-representation of differentially expressed genes involved in the regulation of cell proliferation, cell activation, cell differentiation, cell death and apoptosis processes, as well as the immune response and regulation of angiogenesis, cell adhesion and transcription factor activity ( Figure 4a ; Supplementary Tables S4 and S5 ). To further characterize the differentially expressed genes in SLFN5 depleted U87MG cells, we used the Kyoto Encyclopedia of Genes and Genomes (KEGG) database to determine biochemical pathway enrichment. There were several pathways significantly enriched in SLFN5 depleted cells compared to WT cells, including the TGF-beta signaling cascade, glycine, serine and threonine metabolism pathways, the complement and coagulation cascades, Jak-STAT signaling pathways, and ECM-receptor and cytokine-cytokine receptor interaction pathways (Supplementary Figure S2 and Supplementary Table S6 ). Next, to gain functional insights into the gene interactions, we applied Ingenuity Pathway Analysis for any relationships that may exist among the differentially expressed genes. Cellular growth and proliferation (Supplementary Figure S3C ) along with cell cycle (Supplementary Figure S3D) were identified as the top-scoring IPA gene interaction networks.
It is well established that many mammalian genes have multiple transcript variants and protein isoforms, mediated by alternative splicing. 22 Studying these dynamic events requires an efficient way of detecting these changes at the transcript level. 23, 24 Here (c and d) U87MG SLFN5 WT and KO cells were subjected to invasion assays and cells that invaded through the matrigelcoated transwell inserts were stained and counted. Data are expressed as numbers of invading cells for each cell line and bar graphs represent means ± s.e.m. of three independent experiments. All micrographs were taken at the same magnification. (e and f) Representative images and quantification of tumor cell invasion are shown. U87MG SLFN5 WT and KO spheres were subjected to 3D matrigel invasion assay and the invaded area was measured after 24 and 72 h. Data are expressed as invaded area by each cell line at the time points indicated and bar graphs represent mean ± s.e.m. of three independent experiments. One-way analysis of variance was used to assess statistically significant differences between the groups (NS, not significant, *P o0.05). All micrographs were taken at the same magnification. (g) U87MG SLFN5 WT and KO cells (1 × 10 6 cells in 100 μl of Matrigel) were injected into the right and left flank of nu/nu mice, respectively (n = 8). Tumor volume was measured every other day for 26 days. Graph represents mean ± s.e.m. of change in tumor volume (y axis) as a function of the time (x axis) after the injection. Multiple t-tests analysis was used to assess statistically significant differences between SLFN5 WT and KO tumors (*P o0.05). (h) Time to tumor onset in mice injected with SLFN5 WT and KO cells. Time to tumor onset was assessed by physical palpitation. (see also Supplementary Figure S1 ). Role of SLFN5 in glioblastoma we applied a complementary analytical approach, Cuffdiff, an algorithm that robustly tracks the dynamics of individual transcript expression. 25 The gene set enrichment analysis at the isoform level revealed regulation of inflammation-associated processes and negative regulation of cell proliferation or angiogenesis (Figure 4a , Supplementary Table S7 ). Consistent with these data, Figure 4 . For caption see page 6012.
differential transcript expression of SLFN5 target genes, as well as cell cycle and proliferation related genes, revealed distinct clustering of SLFN5 KO and WT cells (Figures 4b and c ), suggesting a regulatory role for SLFN5 at the transcriptional level. Because SLFN5 is associated with IFN signaling, we analyzed the Interferome v2.01 database 26 to interrogate the effects of depletion of SLFN5 on IFN signaling-associated genes. We identified a large subset of genes primarily involved with the IFN pathway (115/238, 48.3%), that differentially cluster in WT and KO cells (Figure 4d ). A Volcano plot of differentially expressed genes for KO versus WT cells revealed significant downregulation of SLFN5 in edited U87MG cells (Figure 4e ). We validated downregulation of EFEMP1, 27 LOX 28 and LAMA4, 29 previously identified as genes that promote malignant phenotypes, along with SLFN5 ( Figure 4f ). Collectively, these results underscore the involvement of SLFN5 in coordinating proliferation and inflammation signals through regulation of critical nodes in GBM.
SLFN5 interacts with STAT1 and exhibits ISRE repressor activity
To identify the potential mechanism(s) by which SLFN5 exerts its repressor effects on ISGs, we undertook studies to determine SLFN5-protein interactions using mass spectrometry analysis of associated proteins in cells overexpressing SLFN5. SLFN5-protein complexes immunoprecipitated from 293T cells carrying inducible Myc-tagged SLFN5 were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis and visualized with Bio-Rad stain-free technology (Figure 5a , left panel). Next, the protein complexes were extracted and subjected to mass spectrometry analysis using the Velos Orbitrap platform that generates sequence information on individual peptides, later converted into 32 unique proteins (Figure 5a , middle panel and Supplementary  Table S8 ). Classification according to functional relationships between the putative SLFN5 interactors revealed enrichment of proteins involved in the immune response, response to stimulus, viral reproduction, metabolic process and establishment of localization GO terms (Figure 5a , right panel). Among the proteins detected in association with SLFN5 by the mass spectrometry analysis, was STAT1, a key element of Type-I IFN-mediated signaling and the IFN-response. 4, 10 To determine if SLFN5 interacts directly with IFN-activated STAT1, co-immunoprecipitation analyses were performed in the same 293T cells carrying inducible Myc-tagged SLFN5. The association of SLFN5 with protein members of the STAT family was established by immunoblot analysis, using anti-STAT1, anti-STAT3 and anti-STAT5 antibodies in immunoprecipitated protein lysates ( Figure 5b ). SLFN5 was found to be associated with STAT1, but not STAT3 or STAT5 (Figure 5b ) and the signal was more intense after 24 h of IFNβ treatment (Figure 5c ). Collectively, our findings suggested that SLFN5 protein exhibits specificity for STAT1, suggesting a potential role for SLFN5 in the regulation of STAT1-mediated type-I IFNinduced transcriptional activation of ISGs.
To further understand and define the functional outcome of this SLFN5-STAT1 interaction, we examined whether there is enrich-ment of SLFN5 in the promoters of STAT1 target genes, using chromatin immunoprecipitation (ChIP) assays. For this, we employed the ISG15 promoter that has multiple STAT1 binding sites 30, 31 (Figure 5d ). We used a lentiviral-based doxycyclineinducible gene expression system to overexpress Myc-tagged SLFN5 fusion protein in HEK-293T cells. Cells were either mocktreated or treated with doxycycline for 72 h prior to the start of IFNβ treatment. Lysates of IFNβ-treated Myc-tagged SLFN5 overexpressing cells and control HEK-293T cells were immunoprecipitated with ChIP grade antibodies for Myc-Tag or control mouse immunoglobulin G. After column purification, the precipitated chromatin DNA fragments were used as templates for quantitative real-time RT-PCR, with two specific ChIP grade primers for the indicated binding sites (Figure 5d ). The specificity of the assay was monitored by including a primer set that targets a non-STAT1 binding site (Figure 5e, right panel) . There was no detectable enrichment for non-specific regions with the mouse immunoglobulin G antibody. In the absence of doxycycline treatment there was no significant enrichment of SLFN5containing complexes to the ISG15 promoter sites 1 and 2 (Figure 5e , left and middle panels). However, there was significant enrichment of SLFN5-containing complexes to both ISG15 promoter sites in HEK-293T overexpressing SLFN5 cells treated with IFNβ ( Figure 5e , left and middle panel). Taken altogether, these data strongly suggest that SLFN5 is present together with STAT1 in a complex that binds to IFN-stimulated response elements (ISRE) in the promoters of ISGs.
Crispr/Cas9-mediated SLFN5 gene disruption enhances IFNβ-dependent gene transcription Having demonstrated that SLFN5 interacts with STAT1 upon IFN treatment, we further examined the role of SLFN5 in IFN-induced ISG transcription. We employed Human HT-12 v4 Expression BeadChip microarrays to identify genes differentially induced by IFNs in SLFN5 WT and SLFN5 KO U87MG cells. Putative probes with fold change threshold 41.5, significance level of Benjamini and Hochberg false discovery rate o0.05 were deemed to be significantly differentially expressed. Analysis of gene expression profiles from three independent experiments revealed that 439 genes were upregulated in IFN-treated SLFN5 WT cells (Figure 6a ), whereas 566 genes were upregulated in IFN-treated SLFN5 KO cells (Figure 6b ). 53 induced genes were detected in SLFN5 WT, but not in SLFN5 KO cells (Figures 6c and d , Supplementary Table  S9 ). 180 uniquely induced genes were identified only in the SLFN5 KO cells, but not in SLFN5 WT cells (Figures 6c and f , Supplementary Table S9 ). Importantly, among the 386 genes induced in both SLFN5 WT and SLFN5 KO cells (Figures 6c and e ), the expression of 295 of these genes was significantly higher in the SLFN5 KO compared to the SLFN5 WT U87MG cells ( Supplementary Table S9 ), suggesting potential repressive effects of SLFN5 on type-I IFN signaling for the majority of IFN-stimulated genes. In contrast to genes whose transcription was upregulated by SLFN5 depletion, a smaller set of genes was downregulated Figures S2-S3 and Supplementary Tables S1-S7). and there was very little overlap between these genes in SLFN5 WT and SLFN5 KO cells. To further assess the canonical signaling pathways the upregulated genes might be involved in, we performed pathway enrichment analysis using the Ingenuity Pathway Analysis tool 32 ( Supplementary Table S10 ). Overall, depletion of SLFN5 led to the transcriptional enhancement of Figure 5 . For caption see page 6014.
Role of SLFN5 in glioblastoma AD Arslan et al nearly 3/4 of the upregulated ISGs (295 out of 386), establishing a key regulatory role for SLFN5 in IFN-dependent transcriptional responses, which play key roles in antitumor cellular responses. 33 We also examined whether SLFN5 elicits differential transcriptional regulation via ISRE in luciferase reporter assays, by establishing stable ISRE-luciferase reporter expression in SLFN5 WT and KO U87MG cells and JK18, JK46 GSC lines. Treatment with IFNβ for 6 h led to the induction of luciferase in SLFN5 WT cells, but this induction was significantly enhanced in the absence of SLFN5, suggesting that SLFN5 can inhibit IFNβ-induced STAT1 activity (Figures 6g and j) . Conversely, ectopic expression of SLFN5 in a different set of ISRE reporter cells led to decreased luciferase activity (Figure 6h ). When we examined the effects of escalating doses of IFN for a prolonged duration of treatment, we found that in reporter cells with SLFN5 gene disruption, there was enhanced responsiveness, as measured by ISRE driven luciferase activity ( Figure 6i ). As our data demonstrated regulatory effects of SLFN5 on ISRE reporter activity, we determined the effects of SLFN5 depletion on protein expression of the ISG15 gene product, a post-translational protein modifier and important player in the control of IFN responses. 34 Cells carrying doxycycline-inducible SLFN5 shRNA were grown in the presence or absence of doxycycline, and then treated with IFNβ, after which ISG15 protein expression was determined by immunoblotting. As shown in Supplementary Figure S4A , protein expression of ISG15 was induced in response to IFNβ in cells with endogenous SLFN5, but this expression increased further in cells in which SLFN5 was knocked down using doxycycline-inducible SLFN5 shRNA. To further establish the role that SLFN5 protein plays in regulation of ISG15 expression, we ectopically expressed SLFN5 by using a doxycycline-inducible promoter (Supplementary Figure S4B) in U87MG cells and examined the effects on ISG15 protein expression. Consistent with our knockdown studies, ectopic expression of SLFN5 substantially decreased the levels of IFNdependent expression of ISG15 protein (Supplementary Figure S4B ).
To directly examine the function of SLFN5 in type-I IFN-induced gene activation and to validate the microarray results, SLFN5 WT and SLFN5 KO U87MG, JK18 and JK46 cells were treated with IFNβ for the indicated time, or left untreated, and the induction of known ISGs 35, 36 was analyzed by quantitative real-time RT-PCR. As expected, IFNβ treatment led to a robust induction of several key ISGs. We found the induction of ISG54, ISG56, ISG60 and OASL by IFNβ was significantly enhanced in SLFN5 KO cells compared with WT cells (Supplementary Figure S4C) . Similar to GBM cell lines, combination of SLFN5 knockdown and IFNβ treatment resulted in enhanced induction of CXCL10, ISG15, ISG54, ISG56, ISG60, MX1, OAS1, OAS2 and OASL in JK18 and JK46 GSCs (Figures 6k and l) , establishing a critical role for SLFN5 in type-I IFN-signaling in GBM, including their GSC population.
SLFN5 disruption enhances type-I IFN-mediated antineoplastic responses
To determine the potential regulatory effects of SLFN5 on proliferation and survival of GBM, we assessed IFN sensitivity in SLFN5 WT and SLFN5 KO U87MG cells using the Alamar Blue viability assay. Depletion of SLFN5 in U87MG cells resulted in enhanced cellular sensitivity to type-I IFN-induced antiproliferative responses (Figure 7a ). Next, we asked whether SLFN5 depletion sensitizes GSCs to the anti-proliferative effects of type-I IFNs. For this purpose, glioma stem-like cells were cultured in sphere forming conditions, as previously described. 37, 38 Culturing cells under these conditions resulted in enrichment for stem cell markers, such as CD133-encoding PROM1 and NESTIN-encoding NES as compared with monolayer-cultured cells (Figure 7b ). [38] [39] [40] Upon exposure to increasing doses of IFNβ, there was reduced glioma stem-like cells-derived sphere formation, which was clearly more pronounced in SLFN5 depleted spheres (Figures 7c and d) . We next studied the effects of SLFN5 knockdown in the patientderived GSC lines, JK18 and JK46, which express high levels of the stem cell marker CD133-encoding PROM1 gene (Figure 7e ). For this purpose, we used SLFN5 siRNA in JK18 and JK46 GSC lines (Figures 7f and g) . While only a minimal inhibitory effect on neurosphere size was observed after treatment with IFNβ alone, the combination of IFNβ treatment and SLFN5 knockdown resulted in greatly impaired neurosphere growth, as indicated by a substantial decrease in neurosphere size in patient-derived GSC lines, confirming our observations in U87MG cells (Figures 7h-k) . These results strongly suggest that downregulation of SLFN5 leads to enhanced cellular sensitivity to type-I IFNinduced anti-proliferative responses in glioma stem-like cancer cells, suggesting that SLFN5 is an important negative regulator of the IFN response in GSCs. Chromatin-protein complexes were immunoprecipitated with anti-myc-Tag or appropriate immunoglobulin G (IgG) isotype antibodies used as controls. Immunoprecipitated DNA samples were analyzed by qPCR using ISG15 primer set 1, ISG15 primer set 2 and RPL30 primer set. Data are expressed as relative enrichment over untreated (No-DOX) and are represented as mean ± s.d. of two independent experiments. Two-way Anova analysis followed by Tukey's multiple comparison test was used to assess statistically significant differences between experimental conditions. (NS, not significant; *P o0.05; see also Supplementary Table S8 ).
DISCUSSION
In recent years there has been increasing attention directed to the Schlafen family of genes and proteins. This reflects the accumulating evidence that these proteins play key roles in several cellular functions and accumulating data suggest their involvement in the pathophysiology of both neoplastic and nonneoplastic disorders. The original description of the Schlafen gene family arose in the mouse system. 12 Although the initial mouse Figure 6 . For caption see page 6016.
Role of SLFN5 in glioblastoma AD Arslan et al work described four mouse members, there are now over 10 mouse Slfns that have been identified and at least 5 human SLFNs. 12, 13, 41, 42 All Schlafens are characterized by the presence of a Slfn box/domain that is unique for this family, but whose precise function still remains to be defined. 12, 42 The 3 different groups of Schlafens are defined by the size of the proteins and by the presence of unique domains, such as the SWADL domain (Ser-Trp-Ala-Asp-Leu) in groups II and III, a C-terminal extension helicase motif in group III, and a nuclear localization signal in group III. 12, 15 There is evidence that the function of human members of the Schlafen family mediate important biological responses, including antiviral responses. Specifically, SLFN11 blocks HIV-1 production, via its ability to inhibit expression of viral proteins. 43 Other studies have implicated SLFNs in the regulation of malignant cell proliferation. It has been shown that SLFN5 inhibits anchorageindependent growth and invasion of malignant melanoma cells. 13 SLFN5 has also been implicated in the control of motility and invasiveness of renal cell carcinoma cells, a function that reflects its suppressive effects on expression of the matrix metalloproteinase genes MMP-1 and MMP-13, and several other genes involved in the control of malignant cell motility. 14 Such genes include PCDHGB2, PCDHB11, PPL, JUP, KIF1C and TPM4. 14 Notably, these effects of SLFN5 appeared to be specific to SLFN5, since SLFN11, SLFN12 and SLFN13 did not exert any such suppressive effects. 14 Other studies have shown that SLFN11 exhibits a novel function as a sensitizer of malignant cells to different types of chemotherapy. 44, 45 In the present study we provide the first evidence implicating SLFN5 in glioblastoma tumorigenesis and demonstrate a novel function of SLFN5 as a negative regulator of STAT1-dependent transcriptional activation of ISGs. In initial studies, we found that SLFNs are inducible by type-I IFNs in malignant brain tumor cells. Remarkably, and to our surprise, we found that Crispr/Cas9-driven deletion of SLFN5 enhances type-I IFN-induced antitumor activity in glioblastoma and leads to suppression of sphere formation in sphere-cultured glioma and patient-derived cell lines, consistent with inhibitory effects on the malignant GSC population. In efforts to define the functional mechanisms mediating these responses, we found that knockout or knockdown of SLFN5 leads to enhanced expression of ISGs, consistent with a suppressive role of SLFN5 on ISG transcription in glioblastoma cells. Using mass spectrometry analysis, we found that STAT1 associates with SLFN5 in a type-I IFN-dependent manner and is present in complexes that bind ISRE elements in the promoters of ISGs. Thus, SLFN5 appears to act as a repressor of STAT1-driven gene transcription, probably via its direct interaction with the protein. Consistent with this, SLFN5 shows enrichment at the sites that STAT1 interacts within the promoters of the type-I IFN inducible ISGs, and targeted disruption of the SLFN5 gene results in an enhanced global transcriptional response after IFNβ stimulation. These findings for the first time define a member of the Schlafen family as a negative regulator of the type-I IFN response in a given malignant phenotype. This raises the question of whether targeting of SLFN5 may provide a unique approach to treat resistant glioblastoma and/or to eliminate glioma cancer stem cells.
Beyond our findings, there appear to be other examples where human SLFNs may promote tumorigenesis in other systems. For instance, high SLFN5 expression was found to positively correlate with progression to gastric cancer in patients with intestinal metaplasia. 46 On the other hand, it appears that in other tumors SLFN5 may have opposing effects and this variability in elicited biological response may reflect the transcription factors and genes targeted by the repressor activity of SLFN5. In the case of renal cell carcinoma patients, high levels of SLFN5 are associated with better overall prognosis, possibly a reflection of the repressive effects of SLFN5 on the genes for MMP1 and MMP3 and other genes that promote cell motility. Thus, selective targeting of SLFN5 for therapeutic purposes in malignancies in the future may require precise analysis of other associated factors and design of Stably transduced cells were seeded in 96-well plates in triplicated technical replicates and the next day cells were incubated for 6 h in the presence or absence of human IFNβ, and luciferase activity was measured. Data are expressed as fold increase of luciferase activity in response to IFNβ, treatment over control untreated samples for each condition. Bar graphs show means ± s.e.m. of three independent experiments. (h) U87MG cells carrying doxycycline-inducible SLFN5-myc-Tag fusion protein were transduced with an ISRE-luciferase promoter construct carrying lentivirus. Stably transduced cells were grown in the presence and absence of DOX for 48 h, and then seeded in 96-well plates in triplicate technical replicates and the next day cells were incubated for 6 h in the presence or absence of human IFNβ, and luciferase activity was measured. Data are expressed as fold increase of luciferase activity in response to IFNβ treatment over control untreated samples for each condition. Bar graphs show means ± s.e.m. of three independent experiments. (*P o0.05) (i) SLFN5 WT and KO U87MG were stably transduced with the ISRE-luciferase reporter carrying viral particles, as described in Methods section. Equal numbers of stably transduced reporter cells were seeded in 96-well plates in triplicates and the next day cells were incubated with escalating concentrations of human IFNβ as indicated, and luciferase activity was measured. Data are expressed as fold increase of luciferase activity in response to IFNβ, treatment over control untreated samples for each condition. Figure S4 and Supplementary Tables S9-S10).
therapeutic targeting in the context of the specific role of SLFN5 in a particular tumor. Our data suggest that in the case of glioblastoma, a highly fatal malignancy, SLFN5 targeting can be exploited for the development of desperately needed therapeutic approaches. However, for this to be possible, further biochemical characterization of the SLFN5 protein and the function of its various motifs, as well as the SLFN5-containing protein complexes, are necessary. An important issue that, if addressed, may provide the basis for the development of specific SLFN-targeting agents, would be the characterization of the function of the Slfn box motifs that are highly specific for SLFNs, but whose function(s) remain unknown. Also, more detailed biochemical analysis and identification of other transcription factors, beyond STAT1, that may interact directly with SLFN5 and other SLFNs, may provide unique opportunities and new targets for the treatment of glioblastoma and other malignancies.
MATERIALS AND METHODS
Additional materials and methods can be found in the Supplementary Information.
Materials
Recombinant human IFNα was obtained from Hoffmann-La Roche (USA). Recombinant human IFNβ was obtained from Biogen Idec (USA). Adult human normal brain lysate (ab30078) was obtained from Abcam (USA). The antibodies against STAT1, STAT3, STAT5 and Myc-Tag were obtained from Cell Signaling Technology (USA). SLFN5, SLFN11 and SLFN12L antibodies were obtained from Sigma Aldrich (USA). GAPDH antibody was obtained from Millipore (USA). For RNAi mediated gene silencing, cells were transfected with double stranded control non-targeting or SLFN5 targeting RNA oligonucleotides (Santa Cruz Biotechnology, Santa Cruz, CA, USA). For transfection, Amaxa nucleofector kits from Lonza were used according to the manufacturer's instructions.
Cell lines
Glioblastoma cell lines, LN18, LN229, LN443 and U87MG; medulloblastoma cell lines, DAOY and D556, human embryonic kidney 293T cells were all maintained in DMEM and SVGp12 cells were maintained in EMEM, all supplemented with 10% fetal bovine serum and antibiotics. All cell lines were regularly tested for mycoplasma contamination. LN18, LN229, LN443, U87MG, DAOY and D556 cell lines were subjected to short tandem repeat (STR) analysis to ensure genetic stability and authenticated where published reference STR profiles were available (Genetica DNA Laboratories).
Patient-derived GSC lines JK18 and JK46 were obtained from Dr John A. Kessler (Northwestern University) 19, 20 and were cultured in DMEM/F12 (Thermo Fisher, Carlsbad, CA, USA), supplemented with B27 (2%, Thermo Fisher), penicillin and streptomycin (1%, Sigma Aldrich, St Louis, MO, USA), Heparin (5 μg/ml, Sigma Aldrich), EGF (20 ng/ml) and basic FGF (20 ng/ml, Peprotech) and grown as suspension in non-cell culture treated flasks with filter caps.
CRISPR-Cas9 approach to generate SLFN5 knockout U87MG cells
The guide RNA sequences and Cas9 carrying plasmids were purchased from Santa Cruz Biotechnologies. The guide RNA/Cas9 expression constructs were transfected into U87MG cells using Lipofectamine 3000 transfection reagent according to manufacturer's instructions (Thermo Fisher, USA) 48 h after transfection, U87MG cells were cultured in the presence of puromycin (1 μg/ml). Approximately 2 weeks later, puromycinresistant cells were expanded. Lack of SLFN5 protein expression in U87MG knockout cells was confirmed by western blotting with SLFN5-specific antibody.
Lentiviral production and titration
Second generation, integration-deficient viral particles pseudotyped with the VSV-G envelope glycoprotein were produced by transient cotransfection of the relevant transfer plasmid and pMD2.VSV-G, and psPAX2 packaging plasmids into Lenti-X 293 T cell line (Clontech). Supernatant containing virus was harvested 48 h after transfection, centrifuged at 500 g for 10 min at room temperature and then filtered with a 0.45 μm sterile filter to remove the cellular debris. The filtered medium was then concentrated using Lenti-X concentrator (Clontech), and the titer was estimated using the Lenti-X GoStix (Clontech). The particles were then aliquoted and stored at − 80°C.
Statistical analysis
Unless otherwise specified, GraphPad PRISM v6.0 software for Mac (GraphPad Software, Inc) and Student's t-test were used to perform statistical analyses of the data. Error bars are s.e.m. of averaged values for each experimental condition obtained from indicated number of experiments. Sample size was chosen based on similar experiments in previous publications. Similar variance is reflected by small SEM with equal n between the different conditions of a same experiment. P-valueso0.05 were considered statistically significant between means.
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